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Abstract: Since the discovery of PTEN, this protein has been shown to be an effective 
suppressor of cancer and a contributor to longevity. This report will review, in depth, the 
associations between PTEN and other molecules, its mutations and regulations in order to 
present how PTEN can be used to increase longevity. This report will collect recent 
research of PTEN and use this to discuss PTEN’s role in caloric restriction, antioxidative 
defense of DNA-damage and the role it plays in suppressing tumors. The report will also 
discuss that variety of ways that PTEN can be compromised, through mutations, complete 
loss of alleles and its main antagonist, the PI3K/AKT pathway. 
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1. Introduction 
Phosphatase and tensin homolog deleted on chromosome 10 (PTEN, also known as MMAC1 and 
TEP1) was first discovered in 1997 by two independent groups and recognized as the long sought after 
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tumor suppressor gene frequently lost on human chromosome 10q23 [1,2]. This locus is highly 
susceptible to mutation in human cancers: the frequency of mutations have been estimated to be  
50%–80% in sporadic tumors such as glioblastomas, prostate cancers and endometrial carcinomas; and 
30%–50% in lung, colon and breast tumors. PTEN is often associated with advanced cancers and 
metastases [3], due to loss of PTEN having been observed at its highest frequency in late stages of cancers.  
Together with p53, Ink4a and Arf, PTEN makes up the four most important tumor suppressors in 
mammals [4] as evidenced by their overall high frequency of inactivation across a variety of cancer 
types. Because of this, it is vital to understand the mechanisms of how PTEN functions. 
The gene that encodes PTEN is non-redundant and expressed in all eukaryotic cells [5]. While there 
is only one homologue of PTEN found in fungi and lower animals, several orthologues have been 
discovered in mammals, namely TPTE, PTEN2 and TPIP [6–8]. Unlike PTEN, however, these 
orthologues are not ubiquitously expressed in all tissues. TPTE and PTEN2 are only expressed in the 
testis, while TPIP is expressed in the testis, brain and stomach. Whilst the orthologues share PTEN’s 
major function, that of phosphatidylinositol (3,4,5)-triphosphate (PIP3) phosphatase (as will be 
discussed later), analyses have shown that the orthologues are limited to the Golgi apparatus and 
endoplasmic reticulum, while PTEN is expressed in the nucleus, cytoplasm and at the cellular 
membrane. The difference in localization demonstrates that the PTEN orthologues do not regulate 
PIP3 in the same manner as PTEN, reinforcing the non-redundancy of PTEN. 
The PTEN protein contains 403 amino acids and several domains [1]. The crystal structure of PTEN 
shows a 179 residue N-terminal domain and a 166 residue C-terminal domain [9]. The N-terminal 
domain contains a protein tyrosine phosphatase (PTP) signature motif that is similar to dual specificity 
protein phosphatases. The C-terminal domain contains the C2-domain that is responsible for its 
recruitment to phospholipid membranes. The PTEN homologue found in fungi and lower animals lack 
this C2 domain [1].  
While the functions of PTEN will be discussed in depth in the report, in brief the main function of 
PTEN is to antagonize the PI3K/AKT pathway [10], thereby opposing the pathway’s cell proliferative 
response and, more important to longevity, opposing AKT’s downregulation of antioxidant genes and 
proteins [11]. In concert with this function, PTEN has been reported to bind with another antioxidant 
gene, p53, and arresting the cell cycle whilst positively regulating protein dealing with DNA-damage [12]. 
These functions serve not only to extend cellular longevity but also prevent deleterious DNA-damage 
that can lead to malignant tumors [13].  
The purpose of the report is to serve as a comprehensive review of the links that have been made 
between PTEN and the potential effects it may have on ageing. It will cover various issues such the 
regulators of PTEN, the regulatory effects of PTEN, its cellular functions, its associations with cancer 
and its direct effects on longevity in the effort to understand the many and varied pathways that PTEN 
is a part of, and how these intricate and integral pathways are key to effecting longevity. While  
Ponce de León’s dream of a fountain of youth may be unobtainable as of yet, this report will show that 
extended longevity is highly possible. 
This paper follows in theme on recent papers such as Jaskelioff et al. [14] and Ortega-Molina et al., 
which show the strides that anti-ageing research have made over recent years [4,14,15]. PTEN has the 
potential the play a crucial role alongside these other studies as, beyond its documented ability to 
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extend longevity, its function as a tumor repressor is vital to any lasting extended longevity to prevent 
the rise of tumors often associated with extended longevity. 
With recent and current studies already being done on PTEN’s effect on longevity, it is necessary to 
comprehend the basics of PTEN to be able to understand its role in the myriad pathways of the human 
cell. These pathways are interconnected and intertwined with many feedback loops, and finding the 
areas which can be exploited for the betterment of human ageing, whilst at the same time not 
compromising others to our detriment is a very exhaustive process and running a fine line. This is the 
reason for this report, to understand those fundamentals to be able to understand the grander picture. 
2. PTEN Regulations 
2.1. Regulates PTEN 
2.1.1. Mutations 
Of the varied sources that can act as regulators upon PTEN, mutations can have a much more 
significant impact on the structure and function of PTEN as it appears before transcription and 
translation have occurred. PTEN haploinsufficiency (where only a single functional allele remains) 
have been shown to contribute to tumor progression and even minor deficiency of function can aid 
tumor development [16]. This is evident in many cancers and syndromes (to be discussed in depth 
further on) such as Cowden syndrome, whose C2-domain mutations may retain partial or full PTEN 
lipid phosphatase functionality, as seen in biochemical assays [17,18]. By truncating phosphorylated 
residues on the C-terminal, mutations such as these can affect PTEN stability, phosphorylation,  
protein interactions and proper localization [19]. Mutation of Lys289 has also been found to alter  
PTEN localization. 
The Ser380, Thr382 and Thr383 cluster on the C-terminal (referred to as the STT [20]) have been 
shown to significantly negatively affect PTEN stability while positively affecting phosphatase activity 
when mutated [21], despite the fact that mutation of the major sites for phosphorylation, Ser370 and 
Ser385, have been shown to have little effect on PTEN function [22]. Leslie and Downes suggests STT 
phosphorylation renders PTEN into a “closed” state while mutation renders it “open”, increasing 
PTEN’s interaction with binding partners, making it more unstable by rendering it more susceptible to 
proteolysis [22]. Because of this, it has been proposed that PTEN’s basal state is that of a 
phosphorylated, inactive state, being activated by dephosphorylation of the STT cluster to foster 
conformational changes. Further strengthening this hypothesis is the fact that tumor-derived C-terminal 
mutants of PTEN are highly susceptible to proteolysis, indicating the C-terminus to be responsible for 
protein stability [23]. 
Mutations on the N-terminal are also thought to affect the stability of the PTEN protein whilst not 
inactivating phosphatase activity [17]. 
The evidence of mutational regulation of PTEN is further supported by the PTEN hamartoma tumor 
syndromes (PHTS) [24] a group of autosomal dominant syndromes identified by developmental 
disorders, hamartomas, neurological deficiencies and an increased risk of cancer. This shows that loss, 
or mutation, of an allele directly leads to a deficiency of PTEN function thereby resulting in PHTS and 
an increased cancer risk. 
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2.1.2. Transcriptional Regulation 
Despite the fact that the exact nature of PTEN regulation is still unclear, there are a number of 
factors that have been demonstrated to upregulate PTEN transcription. One of these is the transcription 
factor peroxisome proliferation-activated receptor γ (PPARγ), a regulator of glucose metabolism and 
fatty acid storage. PPARγ upregulates PTEN via its selective ligand rosiglitazone on peroxisome 
proliferator response elements (PPRE) identified on the PTEN promoter region [25]. PPARγ is itself 
regulated by oleamide, a fatty acid primary amide that has been implicated in sleep induction and 
hypolocomotion [26], giving an indication of the complex network that surrounds PTEN. In addition, 
ligand-activated PPARδ up-regulates PTEN and suppresses the phosphatidylinositol 3-kinase 
(PI3K)/AKT pathway [27]. Knockdown of PTEN with siRNA abrogated the effects of PPARδ on 
cellular senescence and on generation of ROS in angiotensin II treated vascular smooth muscle cells.  
The early growth-regulated transcription factor-1 (EGR-1) upregulates PTEN messenger RNA, and 
thus protein, expression leading to increased levels to apoptosis (a function of PTEN) [28]. It 
accomplishes this by binding to a functional GCGGCGGCG Egr-1-binding site on an untranslated 
region on the 5' strand. Much like PTEN, EGR-1 is involved in growth restricting and apoptotic 
processes [29] and it has been hypothesized that the interactivity of both proteins is a result of the 
similarity of their functions, that part of PTEN’s apoptotic function is due to EGR-1. This is supported 
by Virolle et al.’s experiment which showed that the introduction of exogenous EGR-1 restored PTEN 
stimulation in EGR-1−/− cells in vitro. 
EGR-1 can also be stimulated by IGF-2 in a negative feedback loop [30]. According to Moorehead 
et al.’s study, IGF-2 regulates and is regulated by EGR-1, and while EGR-1 stimulates PTEN and  
IGF-2 stimulates the AKT pathway [31] (two opposing pathways). Introduction of IGF-2 has been 
found to increase AKT levels in the short term while increasing PTEN levels in the long term. This is 
suggestive of a negative feedback loop to counter the cell-proliferative properties of the AKT pathway. 
Ras, a small GTPase, regulates the passage of extracellular signals to intracellular pathways by 
acting as a molecular switch [32]. Ras can act as an antiapoptotic/cell-survivalist regulator by inducing 
the RAS-RAF-MEK-ERK pathway, down-regulating PTEN via the transcriptional factor c-Jun [33], 
and inducing the AKT-PI3K-NF-kappaB pathway, down-regulating p53 and FoxO genes [34]. It is 
unsurprising, therefore, to discover that Ras is a key oncogenic protein. 
Epigenetic effects may inhibit PTEN expression [35] such as promoter hypermethylation in various 
types of cancer [36–38]. Caution must be taken when interpreting epigenetic silencing regarding PTEN 
as a PTEN-pseudogene exists with a promoter also shown to be methylated [39] although there is 
doubt about the expression of the pseudo-gene [40]. 
PTEN is negatively affected by MicroRNAs (miRNAs) which are short, single-stranded endogenous 
RNAs approximately 22 nucleotides in length that repress mRNA translation. Specifically, it was 
shown that PTEN is inhibited by miR-21 [41,42], one of the most frequently found miRNAs to be 
upregulated in cancer to promote cell proliferation and to inhibit apoptosis [43–45]. This suggests that 
its oncogenic effect is due, at least in part, to its suppression of PTEN. The oncogenic effects of PTEN 
inhibition will be discussed in detail later on. 
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2.1.3. Post-Translational Regulation 
By far the greatest number of regulatory effects on PTEN occurs post-translation, by the interaction 
of other proteins and chemicals on the PTEN protein. The various post-translation modifications that 
may regulate PTEN include phosphorylation, acetylation, oxidation and ubiquitination.  
For example, it has been reported that PTEN stability is subject to various post-translational 
modifications such as phosphorylation of specific residues on its C-terminal tail, as done by protein 
interacting with carboxyl-terminus tail 1 (PICT1) for instance [46], that have been associated with 
increased stability [21,47,48] while phosphorylation of other sites such as Thr366 destabilize  
PTEN [49]. A total of six phosphorylation sites, at Thr366, Ser370, Ser380, Thr382, Thr383, and 
Ser385, have been shown to regulate PTEN tumor suppressing function (by modulating protein 
stability). Phosphorylation also results in decreased catalytic activity toward lipid substrates, resulting 
in a decreased ability to interact with membranes, a key function of PTEN. 
Depletion of serine/threonine-protein kinase (Chk1), a signal transducer in the cell cycle pathway [50], 
decreases phosphorylation and levels of PTEN. Chk1 and PTEN are linked in the cell cycle regulatory 
pathway as phosphorylation of both Chk1 and PTEN recovers the cell cycle after DNA replication has 
stalled. An ATR-Chk1-CK2-PTEN pathway also exists as ATR phosphorylates Chk1 at Ser137, which 
in turn induces casein kinase 2 (CK2)-mediated phosphorylation of PTEN at Thr383 [48]. This is vital 
for recovery of the cell cycle and illustrates the roles of Chk1 and PTEN in DNA damage response. 
Rho-associated protein kinase (ROCK), a protein involved in cellular membrane activities, has been 
shown to increase PTEN localization to the plasma membrane by phosphorylating sites Ser229, 
Thr322, Thr319, and Thr321 in the C2 domain, in contrast to the above mentioned phosphorylation of 
site Thr366 [51]. Phosphorylation of PTEN has also been attributed to glycogen synthase kinase  
3β (GSK3β) [52,53]. 
PTEN contains two PEST-sequence (proline, glutamic acid, serine, threonine) motifs which are 
normally found on short-lived, unstable proteins which are degraded by ubiquitin mediation of the 
proteasome. While PTEN is, under normal circumstances, a stable and long lived protein, studies have 
shown that PTEN may be regulated by the PEST-sequence domains in that the half-life of PTEN is 
increased during proteasome inhibition [48]. It was also shown that exposure to zinc-ions initiated 
ubiquitin-dependent, proteasomal degradation of PTEN [54]. Wu et al. found that proteasome 
inhibition prevented PTEN degradation in response to zinc-ions, suggesting that zinc-ions activate the 
degradation process either through the proteasome or through ubiquitin. 
In contrast to this, however, Tang and Eng found that p53 may destabilize and degrade PTEN in 
cells with proteasome dysfunction [55]. 
Lys13 and Lys289 are two conserved sites identified for PTEN ubiquitination and Trotman et al. 
showed that ubiquitin conjugation to these sites is highly important for the shuttling of PTEN between 
nucleus and cytoplasm [19]. Wang et al. isolated E3 ubiquitin-protein ligase 4-1 (NEDD4-1) and 
showed that overexpression of NEDD4-1 mediated mono- and poly-ubiquitination of PTEN through 
physical interaction [56]. 
The nuclear histone acetyltransferase-associated PCAF protein promotes PTEN acetylation at 
Lys125 and Lys128 during PTEN interaction to decrease the catalytic activity of PTEN [57]. The 
catalytic activity can also be downregulated by oxidation of reactive oxygen species (ROS) which 
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cause the formation of a disulfide bond between Cys124 and Cys71 [58]. This has been seen to either 
take the form of hydrogen peroxide (H2O2) or endogenous ROS produced in macrophages in response 
to cellular and metabolic stress and is associated with oxidant-dependent downstream signaling [59,60].  
Proteins such as Na+–H+ exchanger regulatory factor (NHERF) as well as membrane-associated 
guanylate kinase inverted 2 (MAGI-2) can regulate PTEN localization and recruitment to the 
membrane through the 3 aa C-terminal region on PTEN [47,61]. These PDZ domain interactions can 
be negatively modulated by phosphorylating PTEN on its C terminus [21,23,62]; however, deletion of 
the three aa amino acids does not alter the tumor suppressive activity of PTEN [47]. Table 1 below is a 
brief summary of regulators of PTEN mentioned in this section. 
Table 1. Regulators of PTEN and their effects. 
PTEN regulators Effects 
Haploinsuffiency Reduced PTEN function, higher susceptibility to tumours [16] 
C2-domain mutations Negatively affect PTEN stability, phosphorylation, protein interactions and  
proper localization [17–19] 
N-terminal mutations Negatively affect protein stability [17] 
PPARγ Up-regulation of PTEN transcription [25] 
EGR-1 Up-regulation of PTEN mRNA leading to apoptosis [28] 
Ras Down-regulates PTEn via c-Jun, induces PI3k-AKT pathway [33] 
Promoter hypermethylation Possible inhibition of PTEN expression [35] 
STT phosphorylation Significantly negatively affect PTEN stability while positively affecting  
phosphatase activity [21,22] 
mir-21 Down-regulates PTEN transcription [41–45] 
PICT1 Phosphorylates PTEN C-terminal, increases stability [21,47,48] 
Phosphorylation of T366, 
S370, S380, T382-3, S385 
Affects protein stability and decreases PTEN’s ability to interact with membranes [49] 
Chk1 Induces CK2-mediated phosphorylation of PTEN, recovers stalled cell cycle [48,50] 
ROCK Phosphorylates PTEN to increase PTEN localization to membrane [51] 
PEST-sequences Destabilizes PTEN [48] 
NEDD4-1 Ubiquitinates PTEN via L13, L289 [19–56] 
PCAF Promotes PTEN acetylation to decrease PTEN catalytic activity [57] 
ROS Decreases PTEN catalytic activity [58] 
NHERF & MAGI-2 Regulates PTEN localization and recruitment to the membrane [47,61] 
NFκB Down-regulates PTEN transcription [63] 
2.2. Regulated by PTEN 
2.2.1. In the Cytoplasm 
Of the various molecules that are regulated by PTEN, the most well documented is the 
phosphatidylinositol (3,4,5)-trisphosphate [PtdIns(3,4,5)P3]/Protein Kinase B pathway, otherwise 
referenced as the PIP3/AKT pathway, which PTEN antagonizes [10,64]. PTEN dephosphorylates PIP3 
by removing the D3 phosphate from the inositol ring, resulting in PIP2 [10]. PIP3 is responsible for the 
recruitment of proteins containing pleckstrin homology domains to the cellular membranes, including 
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the AKT isoforms and PDK1 as evidenced upon PTEN inhibition. The AKT pathway promotes cell 
survival and proliferation as will be discussed further on. 
A study done by Vivanco et al. showed that the Jun-N-terminal Kinase (JNK) pathway to be 
activated upon PTEN loss, suggesting it is down-regulated by PTEN [65]. Further investigation led the 
authors to discover this was through the Phosphatidylinositide 3-kinase (PI3K) family of proteins of 
which PIP3 is a part. While PIP3, as mentioned above, is a well-known regulator of AKT, the 
activation of JNK was AKT independent. The exact process how PIP3 activates JNK is as yet unclear [63]. 
Xia et al. showed how JNK, through its upstream protein mitogen-activated protein kinase kinase-4 
(MEKK4), down-regulates the transcription of PTEN by activating the transcription factor NFκB 
whereby it binds to the promoter sequence of PTEN [63]. This suggests a negative feedback loop 
between PTEN and JNK. 
2.2.2. In the Nucleus 
A p53 binding sequence has been identified on the promoter sequence of PTEN and a survival 
mechanism that only functions through the transcription of PTEN [66]. PTEN has also been reported 
to bind to p53’s C-terminus directly via its C2 domain, increasing its stability and transcription and 
therefore increasing p53 protein levels. This is further demonstrated by a study showing the drastically 
reduced half-life of p53 in PTEN-null mouse cells [67] independently of PTEN phosphatase activity, 
suggesting it is the binding of PTEN that gives this result. Contrasting studies have shown, however, a 
marked up-regulation of p53 in the absence of PTEN [68]. In addition, PTEN-loss induced senescence 
is associated with enhanced p53 translation [69]. 
Li et al. showed another method how PTEN can influence p53: by the interaction of PTEN with the 
transcriptional coactivator p300/CBP (CREB-binding protein) [70]. By forming a complex with 
PTEN, p300 acetylates p53 on sites Lys373 and Lys382. This results in stabilization and 
tetramerisation of p53. This in turn allows PTEN to bind to p53, and described above, further 
stabilising the p53–p300 complex allowing a more efficient acetylation of p53. The net result in all of 
this is maximum activation of p53 DNA binding and transcription. Li et al. [70] also showed an 
increase in this process during radiation, implying this process is in response to DNA damage. 
It has been suggested that PTEN has a role in maintaining chromosomal integrity by extensive 
centromere breakage and chromosomal translocations observed in PTEN null cells [71,72]. Puc and 
Parsons showed this to be due to AKT-phosphorylation of CHK1 that leads to sequestration of CHK1 
from the nucleus and, as explained above, induces phosphorylation and levels of PTEN. The regulation 
of centromere stability is done by PTEN physically associating with the centromere binding protein 
Centromere Protein C (CENP-C) [72]. This is done in a phosphatase independent manner but requires 
a functional C-terminus on PTEN’s behalf. Shen et al. also showed that PTEN positively regulates 
Rad51, a protein involved in repairing double stranded breaks, through the transcription factor  
E2F-1 [72]. Table 2 below is a brief summary of the regulatory effects of PTEN. 
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Table 2. The regulatory effects of PTEN. 
Regulated by PTEN Effects 
PIP3/AKT pathway 
Increased longevity [73–76], reduced insulin signalling [77], 
tumour suppression [78], reduced DNA damage [79] 
JNK pathway Downregulated via phosphorylation PI3K [65] 
p53 Increased stability and transcription of p53 [67] 
CENP-C Binds with PTEN, maintains chromosomal integrity [72] 
Rad51 Positively regulated via E2F-1, repairs DSB [72] 
3. Cell Functions 
The regulatory effects of PTEN are synonymous with its cellular functions as PTEN functions by 
affecting a variety of pathways. While the report above focused on the mechanics of PTEN regulations, 
the report below will focus on the effects of this and how it relates to longevity. In Figure 1, one can see 
the major functions of PTEN mapped out and how they relate to longevity. It is important to note that, 
while this section of the report deals with each variable individually, one can see in Figure 1 that it is 
only through a handful of interactions that PTEN has the potential to increase longevity. This is 
because of the crucial link that the PI3K/AKT pathway have within the cellular system as will be 
discussed below. 
Figure 1. Mechanisms connecting PTEN with longevity. The major functions of PTEN can 
be seen here: Through down-regulation of the PI3K/AKT pathway (and thus S6K), there is 
a reduction in cellular transformation, insulin signaling and BAT activation resulting in 
cancer protection, metabolic protection and reduced telomere shortening. By up-regulating 
p53, DNA damage is reduced as well as telomere shortening. The result of these is an 
increased longevity. 
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3.1. PI3K 
The most prominently reported function of PTEN is to antagonize the PI3K signaling  
pathway [10,64,80]. PI3Ks can be stimulated by growth stimuli or insulin stimuli [4], whereupon class 
proteins I of the PI3K family such as PIP2 are catalyzed to convert to PIP3, a second messenger 
protein that stimulates growth, proliferation, survival and inhibition of apoptosis [11,81]. PIP3 is 
responsible for recruiting proteins containing a pleckstrin homology domain to cellular membranes, 
including the AKT isoforms. Once there, AKT isoforms are phosphorylated at two residues: on Thr308 
by PDK1 [82] and Ser473 by mTOR kinase complex 2 (mTORC2) [83] which is required for full 
activation. As such, termination of AKT activity is brought about by dephsophorylating AKT isoforms 
on Ser473 [84,85]. 
AKT is responsible for phosphorylating many cellular substrates to promote survival, growth, 
proliferation and metabolism such as mouse double minute 2 homolog (MDM2), glycogen synthase 
kinase 3 (GSK3), forkhead transcription factors (FOXO), Bcl-2-associated death promoter (BAD), 
Caspace-9, and p27 [86] as well as activating mammalian target of rapamycin complex 1  
(mTORC1) through phosphorylating the TSC tumor suppressor complex and activation of  
Ras-homolog-enriched-in-brain (RHEB), a Ras-related GTPase [87]. There are several feedback loops 
incorporated into this cascade, one negative feedback loop being mTORC1 which works to inhibit 
AKT activation [88] as well as a positive feedback loop, the inhibition of FOXO transcription factors 
by AKT which, when activated, suppresses insulin signaling to initiate the PI3K/AKT cascade [77,89].  
A significant role of the PI3K/AKT cascade is to inhibit apoptosis. One method is by 
phosphorylating pro-caspase 9 on residues Ser196 and Thr125 [90]. Dephosphorylated pro-caspase 9 
binds to, cleaves and activates caspases 3 and 7, which target key regulatory and structural proteins for 
proteolysis, resulting in cell death [91]. Another method is by phosphorylating Mdm2, resulting in its 
nuclear localization leading to the subsequent export and degradation of p53 [92,93], a key aspect of 
PTEN’s pathways as mentioned earlier. 
Another role of the AKT pathway is the dual regulation of the forkhead transcription factors FOXO 
and the NF-κB, the former involved in longevity and the latter in causing the ageing process [73–76]. 
By phosphorylating the FOXO proteins, AKT ensures their retention in the cytosol in a complex with 
the 14-3-3 protein. With reduced insulin signaling, enacted by various methods including a negative 
feedback induced by FOXO, FOXO proteins translocate to the nucleus whereby they form complexes with 
co-activators [94–96]. These complexes then allow FOXO to induce the expression of several antioxidative 
enzymes, stress resistance inducers [94,97], regulation of immunosenescence [98] and oxidative stress. 
Conversely, NF-κB is responsible for down-regulating FOXO and antioxidative proteins [74–76]. 
The importance to longevity here is twofold. Firstly, by inhibiting the PI3K pathway, FOXO 
proteins are indirectly overexpressed leading to an increased antioxidant, stress resistant and immune 
activity. The enhanced antioxidant levels would result in a reduction of DNA-damage and telomere 
damage, for example, the single strand and double strand break lesion induced by reactive oxygen 
species (ROS) [79], whilst the increased stress resistance and immune activity would result in an 
increased capability to fight off disease. 
The second impact inhibition of the PI3K pathway can have on longevity is by the inhibition of its 
cell proliferative abilities [78]. Beyond the decreased risk of cancer that curtailing excessive cell 
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proliferation would bring, apoptosis contains and disposes of cellular toxins that have the potential to 
damage tissues. 
3.2. Membrane 
Das et al. discovered, through the use of a fluorescent mutant version of PTEN, that PTEN is 
expressed at the plasma membrane [99]. This was in contrast to previous studies showing PTEN to be 
expressed only in the cytoplasm. More recent immunohistochemical studies have shown the 
distribution of PTEN various between tissues: in epithelial cells such as skin and colon, between is 
mostly found in the cytoplasm [100,101]; in neurons, fibroblasts, adrenal medulla and thyroid most 
PTEN is in the nucleus [102–104]; polarized MDCK cells show that PTEN localizes at the membrane 
in cell–cell tight junctions [61].  
A possible explanation for the different localization patterns may involve the 50 amino, C2 domain, 
on the C-terminus of PTEN. As mentioned earlier, this region contains multiple residues for 
phosphorylation, such as by CK2 and also a PDZ-binding domain that can bind to MAGI2 [61,99],  
a protein localized at the cellular membrane. At the membrane, PTEN has been implicated to exert 
effects on the cytoskeleton and suppress cell migration [105]. This has been indicated by an increased 
migration in PTEN null embryonic fibroblasts. Elevated PIP3 in these cells activates Rac1 and Cdc42, 
small GTPase mediators of cellular migration [106]. Raftopoulou et al. showed that phosphorylation of 
the Thr383 residue on the C2 domain inhibited PTEN’s effect on migration [107]. 
3.3. Nucleus 
3.3.1. Localization 
It was initially assumed that PTEN was strictly a cytoplasmic protein, due to the reported  
lipid-binding domain, an absence of a nuclear localization signal (NLS) on PTEN, and overexpression 
studies and PTEN antibodies that showed PTEN to be exclusively in the cytoplasm [9,108,109]. It is 
now known, however, to be present and functional in the nucleus [110]. 
More recent studies done with reliable PTEN antibodies have produced immunocytological and 
immunohistochemical data that demonstrates the presence of PTEN in primary, differentiated cells 
such as neurons [111], pancreatic cells [112], vascular smooth muscle cells [113], thyroid tissue [104], 
and in the intestinal mucosa [19]. Ginn-Pease and Eng showed that the concentration of nuclear PTEN 
mirrors that of cytoplasmic PTEN during the cycle [114]. The highest concentration of nuclear  
and cytoplasmic PTEN is during the G0–G1 phase when the cell is quiescent or undergoing  
protein synthesis. In contrast, rapidly cycling cell lines have shown a marked decrease in PTEN  
localization [111,114,115] indicating that the nuclear localization of PTEN may not only be dependent 
on cycle stage but also on differentiation status. 
Mechanisms by which PTEN enters the nucleus include diffusion, active shuttling,  
cytoplasmic-localization-signal-dependent export and monoubiquitylation-dependent import [116]. 
PTEN has also been associated with the Major Vault Protein (MVP), a nuclear-cytoplasmic transport 
protein which was found to mediate PTEN nuclear importation. This is dependent on NLS-like residue 
sequences on PTEN: NLS4 (amino acids 65–269 KKDK), NLS2 (amino acids 60–164 RTRDKK) and 
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NLS3 (amino acids 233–237 RREDK) [117]. NLS4 is necessary for PTEN importation but requires 
either NLS2 or NLS3 for proper function. These allow MVP to mediate PTEN and Chung et al. found 
this process to be independent of PTEN phosphorylation and of its phosphatase activity [117]. 
It was more recently reported that nuclear transportation of PTEN is cell cycle dependent and 
regulated by the PI3K/AKT/mTOR/S6K signaling cascade [118], specifically the export through S6K 
phosphorylation of PTEN and a CRM1-dependent mechanism mediating its export. Activation of S6K 
initiates a negative feedback loop by inhibiting IRS-1, slowing the PI3K/AKT cascade, but not 
stopping it due to activation by growth factors. As PTEN is implicated in cell cycle arrest, it has been 
suggested that this export is a method of controlling this arrest. 
3.3.2. Nuclear Interactions 
PTEN has been implicated to play a role in a variety of nuclear functions such as chromosome 
stability, DNA repair, cellular stability and the aforementioned cell cycle arrest. Chang et al. found that 
oxidative stress retards the nuclear exportation of PTEN due to the dephosphorylation of Ser380,  
thus accumulating PTEN in the nucleus [12]. This, the authors found, allows PTEN to bind to p53  
(as shown above) and enhance p53-mediated functions, which showed a decrease in cellular ROS in a 
p53-dependent manner and an increase in the p53 downstream antioxidant gene Sestrin.  
PTEN was also found to arrest the cell cycle via p53 during the G1 phase, suggesting that the cause 
of this was for DNA repair [12]. It was also found the PTEN could arrest the cell cycle at the G1 phase 
by suppressing the transcription of cyclin D1 through phosphorylation of the MAPK pathway [119] or 
by limiting its nuclear accumulation [120]. 
PTEN was shown to increase chromosomal stability by binding to CENP-C to associate with the 
centromere and by increasing the transcription of Rad51 to repair double-strand breaks, independent of 
its phosphatase functions [71,72]. The importance of stable and integral chromosomes cannot be 
understated. Poor chromosomal stability due to DSB has been found to lead to loss of heterozygosity 
leading to tumorogenesis (as reviewed in van Gent et al. [121]). Defects in the centromere, acting as 
the locus to which the spindle microtubules bind [122], would disrupt the process of correct 
segregation of chromosomes to each daughter cell during mitosis.  
With all of these functions taken together, it can be argued that the reason for the cell cycle arrest 
during the G1 phase is to reduce DNA damage by reducing oxidation, to repair DSB and to enhance 
centromere integrity. It is surprising then to find that the most reported function of PTEN—that of 
regulating the PI3K/AKT pathway—is not involved; in fact it has been reported that only cytoplasmic 
PIP3 is sensitive to PTEN [123]. However, it was found that enforced nuclear PTEN expression can 
reduce cellular levels of phosphorylated AKT [19]. 
3.4. DNA Damage 
If ageing can be described as the increase in entropy of life sustaining systems, then that increasing 
entropy is due in large part to the accumulation of damage to DNA. In this report, one has seen that 
PTEN is a crucial factor regarding longevity. It can aid in caloric restriction, preventing an abundance 
of the sources of ROS from entering the cell; it enhances p53’s antioxidant capabilities, preventing the 
accumulation of ROS already in the cell; in a complex with p53 it helps repair DNA damage and 
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through suppression of the PI3K/AKT and other pathways it prevents the emergence of tumors, 
malignant or otherwise. Through all these functions, PTEN promotes longevity. But one of, if not the 
key factor in longevity is DNA damage. Beyond the prevention of tumors, this prevents aberrant 
proteins and cells accumulating in tissues and further increasing the deterioration of the life  
sustaining systems.  
The deterioration within liver tissues due to accumulation DNA damage is a robust biomarker for 
ageing [124,125] and Ortega-Molina et al. found through immunofluorescence that PTEN transgenic 
mice showed a significantly reduced level of DNA damage in the liver compared to control mice. This 
effect was more pronounced the older the mice were. The older transgenic mice also performed 
significantly better during exercise tests, suggestive of good health.  
Whether through exogenous (radiation) or endogenous (ROS via metabolic processes) agents, 
cellular DNA is constantly under stress which can result in errors occurring during replication or 
mutations and other lesions. There are several DNA repair mechanisms which can effectively, in most 
cases, repair such lesions. These include nucleotide excision repair (NER), base excision repair (BER), 
mismatch repair (MMR), DNA double strand break repair (DSBR) and postreplication repair  
(PRR) [126–128]. The NER and BER pathways are most typically activated in response to damage 
done to individual bases. Single strand breaks (SSBs) and double strand breaks (DSBs) on the other 
hand require repair through more complex mechanisms such as homologous recombination (HR),  
non-homologous end joining (NHEJ) or single strand annealing (SSA) [129,130]. 
Of these, NER is the most versatile and flexible repair mechanism which has been conserved in 
most organisms, especially eukaryotes [131–134] and is crucially important in repairing lesions caused 
by UV [135,136]. This pathway involves proteins, such as downstream proteins of p53, which can 
detect, unwind and remove damaged DNA. There are two forms of NER: if the damage is linked to 
transcription there is transcription-coupled repair (TCR); if it is found to be linked to the genome in a 
general sense there is global genome NER (GG-NER). Linked to the NER pathways are the DNA 
damage response (DDR) pathways [137] which are activated to regulate cell cycle transitions, DNA 
repair and replication and apoptosis, processes which involve PTEN either indirectly or directly. 
In studies using low suberythemal UV radiation, mice with down-regulated PTEN in epidermal 
cells showed a predisposition to skin tumors [13]. PTEN has been found to be significantly  
down-regulated in human skin malignant and premalignant lesions. As NER has been linked to UV 
based DNA damage repair, this strongly implicates PTEN in NER-related activation. 
PTEN has also been indicated to positively regulate GG-NER activation through the promotion of 
XPC transcription in keratinocytes. XPC in turn is impaired via PTEN loss, crippling GG-NER. This 
occurs due to the AKT/p38 pathway which is critical for regulating XPC levels, through the increased 
nuclear translocation of the transcription repressor p130 [138]. Thus, PTEN positively regulates  
GG-NER through the suppression of AKT following DNA-damage [13].  
As stated in previous sections, PTEN has a positive effect on DSBR through the up-regulation of 
Rad51. Various organisms studied with PTEN loss have shown evidence of DSBs and defective  
DSBR [72]. This has been disputed, however, by [139], who found that the initial phase of DNA 
damage sensing and modification that has been associated with DSBs is similar in cells with or without 
PTEN. As the authors used different cell lines than previous studies, this may suggest that PTEN’s role 
in DSBR is tissue specific. 
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Chk1 and Chk2, as well as regulating PTEN, play a significant role in DNA repair, activated by 
ATR [140], by activating p53 among other effectors [141,142]. 
3.5. Stem Cells 
PTEN’s effect on stem cells originates from its influence on the regulation of cell growth and 
proliferation through the inhibition of PIP3. Three studies [81,143,144] found that PTEN deficiency in 
neuronal stem cells provided a strong proliferative response and promoted a greatly enhanced  
self-renewal capacity. This enhanced self-renewal capacity was found to be due to PTEN not being 
present to arrest the G0–G1 cell cycle and the decreased growth factor dependency of Pten null 
neural/stem progenitor cells. This was discovered through the deletion of PTEN in murine brains that 
led to macrocephaly (enlarged brains) and disturbing patterning of brain structures due to increased 
cell proliferation and decreased cell death. Follow up ex vivo experiments showed that PTEN loss 
dramatically increases total number of neurons in fetal brain and, more importantly, an increase in the 
number of neuronal stem cells capable of growth. 
Zhang et al. found that deletion of PTEN in the murine hematopoietic system resulted in the 
depletion of current hematopoietic stem cells (HSCs) and increased the proliferation of leukemogenic 
stem cells [145]. The result of this was the mice developed myeloproliferative disorders which 
eventually led to leukemia. Yilmaz et al. in turn demonstrated that treating murine PTEN null cells 
with rapamycin, an mTOR inhibitor, blocked the growth of the leukemogenic stem cells and increased 
the proliferation of normal HSCs [146]. This strengthens the theory that PTEN’s effect on stem cells 
arises through its regulation of the PIP3/AKT pathway. 
3.6. Senescence/Apoptosis 
As PTEN has been shown to increase antioxidant activity, it seems counterintuitive that PTEN 
could promote senescence or apoptosis, especially when one considers that complete acute loss 
promoted a strong senescence response that opposes tumor progression [68], even though complete 
loss of PTEN has been found in many cancers, leading to speculation that loss of PTEN leads  
to tumorogenesis. 
Be this as it may, Gil et al. showed that apoptotic stimuli promote the nuclear import of PTEN, 
implying the nuclear functions of PTEN include apoptosis [119]. While the mechanisms of PTEN’s 
pro-apoptotic functions are still unclear, PTEN has been found to augment doxorubicin-induced 
apoptosis in PTEN-null Ishikawa cells (cells that express truncated PTEN proteins) [147]. Of note in 
this study was that the doxorubicin reduced the levels of phospho-AKT/PKB suggesting PTEN role in 
apoptosis is through its regulation of the PIP3/AKT pathway. This hypothesis is supported by 
Vasudevan et al.’s, study that showed that NFκB, upregulated by AKT, suppresses PTEN activation 
which reduces apoptosis [34]. 
PTEN has also been found to induce apoptosis in a PI3K/AKT independent manner, through the 
association of p53. Much as PTEN and p53 work together to induce cell cycle arrest, it has been found 
that p53, in association with its family members p63 and p73, can activate apoptotic genes in response 
to DNA-damage [148] and that a p73-PTEN complex enhances this response [149]. This at first 
appears to be in direct contrast to the above stated antioxidant activities of PTEN-p53 in response to 
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DNA damage, but much as Wan et al. found that the level of doxorubicin affected the activation of 
PTEN induced apoptosis [147], the degree of DNA-damage may indicate whether PTEN-p53 would 
induce apoptosis or antioxidant release. 
As the apoptotic functions of PTEN are controversial, it is difficult to ascertain the effect on 
longevity. Speculation, however, is that apoptosis effectively removes potentially harmful cellular 
toxins, misfolded proteins and damaged DNA from the system by destroying the cell [150,151]. This 
removes the potential for malignant cells or for these toxins to spread. While not a direct influence on 
longevity as has been seen elsewhere, this cellular housekeeping functions to keep tissues and organs 
healthy, indirectly increasing longevity.  
3.7. Caloric Restriction 
A major breakthrough in the study of PTEN and how it relates to longevity has been the recent 
study done by Ortega-Molina [4]. Of special interest was not the link between tumor suppression and 
longevity as has been found with other tumor suppressors such as p53, Ink4a, Arf [124,152], but the 
effect PTEN has on caloric restriction and the implications this has for longevity.  
Ortega-Molina et al.’s study [4] showed both a median and mean increase in survival and longevity 
(between 9% and 16%). Testing showed this was due to the PTEN transgene, independent of other 
variables. It was observed that the PTEN transgene extended longevity independently of its tumor 
suppressive functions, as cancer-free mice also showed a significant increased longevity. This would 
leave its effects on the PI3K/AKT pathway, nuclear functions and/or insulin pathways to be the culprit. 
The authors found that PTEN transgenic mice, both young and old, had lower fasting levels of 
glucose and insulin serum levels, and a significantly lower value of the insulin resistance index 
HOMA-IR compared with the wild type control mice. This observed effect has been a widely reported 
feature of long lived mice, namely that of a decreased insulin and insulin-like growth factor 1 (IGF1) 
signaling (IIS) pathway [153,154]. This comes to pass through negative feedback routes from the IIS 
pathway itself [77,89,155]. 
Ortega-Molina et al. further explored these negative feedback signals, especially in white adipose 
tissue (WAT) and found the main perpetrator was S6K which, along with mediating the nuclear export 
of PTEN as mentioned above, acts as a primary negative feedback signaler of the IIS pathway [156,157]. 
The WAT of transgenic PTEN mice presented reduced levels of AKT (as expected of increased PTEN 
activation) and also lower levels of phosphorylation in two relevant substrates of S6K, namely S6 and 
IRS1. S6K-mediated phosphorylation of IRS1 at Ser636/Ser639 is inhibitory for insulin signaling 
resulting in insulin resistance. Due to increased PTEN activation, the AKT pathway, which includes 
S6K, would be reduced, leading to less phosphorylation by S6K of IRS1 and thus, less insulin 
resistance. The authors further strengthened this hypothesis by feeding the mice, control and transgenic, 
a high-fat diet for six months (a well-established technique for inducing metabolic stress, insulin 
resistance and liver steatosis) and found that while the transgenic mice increased their body weight at 
similar levels to control mice, they were responsive to insulin injections while control mice were not. 
Control mice were also shown to have extensive liver steatosis while transgenic mice showed minimal 
or no signs. 
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Caloric restriction (CR) has been tested and observed in many organisms, including nematodes, 
mice and humans, and has been attributed to the effect of oxidation [158] from the IIS axis [15,159]. In 
C. elegans specifically, decreased PI3K (AGE-1) and increased PTEN (DAF-18) result in extended 
longevity [160–162] and in mice, reduced IIS activity also yields and extends longevity [4,154]. 
Studies show that CR results in decreased levels of IGF1, a potent stimulator of IRS1 and thus the 
PI3K pathway [163–165]. 
A commonly observed feature of long-lived mice, along with decreased IIS axis activity, is 
improved insulin sensitivity [153]. This is due to the earlier mentioned reduction in the negative 
feedback loop stemming from S6K [77,89,155]. Supporting this, the transgenic mice in Ortega-Molina’s 
study showed lower fasting levels of glucose and insulin serum levels and significantly lower value of 
the insulin resistance index HOMA-IR [4]. Serum levels of IGF1 were also significantly, if 
moderately, lower in transgenic mice than their controls. 
Despite being hyperphagic, these transgenic mice had a decreased body weight compared to control 
mice (27%–28% decrease in young mice, 35%–44% decrease in old mice) [4]. Transgenic mice had a 
higher resting metabolic rate relative to lean mass, and this was shown to be an effect of PTEN 
independent of lean mass. Respiratory quotients and body temperature were ruled out as possible 
explanatory factors. Epididymal white adipose tissue (WAT) relative to body mass was also 
significantly lower in transgenic males, as well as serum levels of leptin and cholesterol.  
The brown adipose tissue (BAT) of transgenic mice also showed an increased activity. This is 
significant as BAT is an efficient source to dissipate heat [166,167], and the significant uptake of 
glucose in the BAT observed in the study suggests that the reduced weight of the transgenic mice may 
be due in part to their increased energy expenditure. 
The importance of this to humans is twofold. Firstly, PTEN encourages calorie restriction which, 
through the decreased activity of the IIS axis and PI3K/AKT pathway, enhances longevity. Secondly, 
PTEN reduces insulin resistance, assists weight loss and lowers cholesterol, which when taken  
together means PTEN is crucial in the fight against diabetes, obesity and high blood pressure, again  
enhancing longevity. 
4. Cancer Properties 
There are two reasons that PTEN’s association with cancer is presented below. The first and most 
obvious reason is that cancer prevention is a straightforward extension of one’s longevity by preventing 
the possible mortality associated with cancer. While it has no effect on the genetic enhancement of 
longevity, it cannot be understated that prevention of an illness is key to extended longevity.  
The second reason for its inclusion in this report is that PTEN’s functions in relation to cancer are 
closely linked to its nucleic and cellular functions. Its inhibition of the PI3K/AKT pathway and its 
functions with p53 in DNA-damage are used for normally functional cells as well as often damaged 
and deteriorated cancer cells. It is by the inhibition of normal PTEN functions that malignant tumors 
may form. 
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4.1. Mutations 
4.1.1. Complete Loss/Haploinsufficiency 
As with mutations that have a regulatory effect on the function of PTEN, mutations of PTEN is also 
a leading cause of cancer, with an estimated 50%–80% of sporadic tumors (includes endometrial 
carcinoma, glioblastoma and prostate cancer) and at 30%–50% in breast, colon, and lung tumors 
having monoallelic mutations of PTEN in common [1,109,168,169]. Complete loss of PTEN is 
associated with advanced cancers, metastases, and more recently been observed to be common in 
breast cancers caused by BRCA1 deficiency [170], and have been found mostly in endometrial cancer 
and glioblastoma [3]. 
Complete loss of PTEN is not certain to cause cancer, as it needs certain circumstances. Studies 
done on mice have shown that complete loss of PTEN is lethal in early development, yet heterozygous 
mice were viable only to develop a variety of tumors in later life [171]. More recently, however, a 
study showed that complete acute loss of PTEN did not induce hyperproliferation as expected, but 
promoted a strong p53-senescence response [68]. This suggests that complete loss of PTEN, in the 
absence of other mutations, may be detrimental to tumor growth, in contrast to the above finding of 
PTEN loss in various cancers. It does provide evidence though for why PTEN haploinsufficiency is 
more often presented in cancer than complete loss of allelic function. 
The notion that complete loss of PTEN does not have a direct effect on cells, rather an indirect 
effect through downstream substrates is strengthened by several studies that have conditionally 
mutated both PTEN alleles using lox recombination to promote Cre recombinase specific tissues, both 
germ cells and somatic cells. The result was mutational inactivation of PTEN. This loss did not  
result in oncogenesis, rather subsequent generations of these PTEN null cells transformed into  
malignancies [81,144,172–174]. This suggests that, like the senescence response via p53, this 
oncogenic response is through another downstream effector of PTEN, possibly PIP3/AKT. 
As reviewed in Salmena et al., various mechanisms can create a gradual loss of PTEN and thus a 
gradation of tumor suppression, ranging from 0% loss to 50% heterozygous to 100% (homozygous) 
loss [20]. These mechanisms can include mutations, transcriptional repression, post-translation 
modification, epigenetic silencing and aberrant localization, many of which have been reviewed earlier 
in this report. Many of these, in combination, can create a continuum of PTEN functionality. For 
example, in mice PTEN is haploinsufficient for tumor suppression and thus 50% of total PTEN is 
insufficient for tumor suppression.  
Other studies using PTEN haploinsufficient mice have shown favorable tumor conditions where 
mice develop colonic adenomas, lymph node hyperplasia and prostate tumors at greater rates than 
controls due to deregulation of the PI3K/AKT pathway [16,175]. Other studies with mice have shown 
that loss of one PTEN allele promotes development of lethal polyclonal autoimmune disorders [176] 
and that PTEN heterozygosity is a driving force for epithelial cancers like prostate cancer [177], 
suggestive of PTEN haploinsufficiency.  
Despite this evidence, the theory that PTEN is haploinsufficient is still undetermined, although 
there are reports that substantiate this. However, PTEN is haploinsufficient for PHTS due to PTEN 
heterozygosity results in distinctive phenotypes such as developmental disorders and benign polyps; 
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PHTS also severely increases the risk of developing malignant tumors [178]. Tumors that have been 
derived from individuals with Cowden syndrome have a tendency not to present detectable  
biallelic mutations of the PTEN gene [179], suggesting only one allele remains, strengthening the 
haploinsufficiency hypothesis. 
4.1.2. Germline Mutations 
Germline mutations of PTEN have mostly been found in hereditary, autosomal dominant cancer 
syndromes with shared characteristics such as developmental defects and disorders, neurological deficits, 
multiple benign hamartomas and an increased risk of cancers. The aberrant growth and hamartomas 
have been shown to penetrate all three germ layers [180], evident of a mutation in the germline.  
These syndromes are Cowden syndrome, Lhermitte–Duclos disease, Bannayan–Riley–Ruvalcaba 
syndrome, and Proteus syndromes which collectively make up PTEN hamartoma tumor syndromes 
(PHTS) [92,181–183]. These have been associated with the deregulation of the PI3K/AKT pathway 
and PI3K inhibitors have been suggested as potential treatments [184]. Mice with PTEN  
mutations have been shown to be susceptible to tumors in various organs such as skin, prostate and  
mammary glands [13,185–188]. 
More recently, studies have reported PTEN germline mutations in patients with macrocephaly, 
mental retardation and autism spectrum disorders, while showing little to none of other PHTS 
symptoms [189]. These studies have shown that as many as 10% of cases involving autism spectrum 
disorders and macrocephaly had PTEN germline mutations [190]. While the connection between 
PTEN mutations and these neurological disorders remain unclear, much like PHTS, there have been 
associations made with the PI3K/AKT pathway. 
4.1.3. Somatic Mutations 
Somatic mutations of PTEN have been documented in a variety of cancers and tumors, both at early 
and advanced stages. These mutations can lead to several different results: either inactivation of 
PTEN’s phosphatase activity through mutation on the C-terminal or partial or total loss of either 
mRNA and/or protein expression [191]. While typically a mutation is accompanied by loss of 
heterozygosity, resulting in the above mentioned possible haploinsufficiency, some tumors have 
appeared to evolve mechanisms to reduce concentration of PTEN without visible mutations of  
the gene [109]. 
Of note is that the frequency of PTEN mutation is nearly as great as that of p53 [171] and that both 
have been associated with total inactivation. Both have been putatively linked to stimulation of the 
PI3K/AKT pathway. With the closely linked activities of both genes in cancer suppression, cell cycle 
arrest and DNA-damage repair, it is unsurprising that both would be targeted for mutation.  
PTEN mutations have also been studied in model organisms such as Drosophila where it alters cell 
size, proliferation, apoptosis and cell migration [78,192,193], much like in humans. However,  
tissue-specific PTEN mutation in mice revealed that, among several phenotypes, PTEN inactivation 
did not result in tumors but created an environment that selects for tumor growth. This is potentially 
linked with the above mentioned Cre recombinase experiments. 
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4.2. Regulatory Effects Causing Cancer 
Unsurprisingly, the regulatory effects of/on PTEN implicated in cancer development will have close 
ties with the previous section on regulation of PTEN. This is because, as PTEN is a tumor suppressor, 
its effects on tumors are only observed once it becomes inactive or down-regulated. While the earlier 
section focused on the mechanisms of regulation, this section will focus on the effects.  
Reports have indicated that a large part of PTEN’s tumor suppression is due to its nuclear functions. 
It was found that the absence of nuclear PTEN is commonly associated with the more aggressive 
diseases in patients with cutaneous melanoma [194,195], large B cell lymphoma [196], colorectal 
cancer [197], esophageal squamous cell carcinoma [198] and pancreatic islet cell tumors [112]. In 
these studies, the absence of nuclear PTEN is more markedly observed in undifferentiated and 
metastatic tumors [104]. With this, Liu et al. (2005) found that forced nuclear expression of PTEN 
antagonizes anchorage-independent growth [199].  
A more general study regarding the tumor suppressive functions of PTEN was done by  
Ortega-Molina et al. [4]. Therein, the authors found that mice with an extra transgenic PTEN gene had 
significantly less incidence of fibrosarcomas than wild type mice. Histological exploration revealed a 
significantly reduced number of malignant tumors, most notably lymphomas and histiocytic sarcomas 
in transgenic mice. 
While the exact mechanisms and causes are as of yet unclear, it can be suggested that the nuclear 
co-operation between PTEN and p53 in regards to DNA-damage may be significant. These two genes 
can arrest the cell cycle, leading to senescence and can initiated DSB repair of damaged DNA as well 
as other antioxidant effects through downstream effectors of p53. The antioxidant properties can 
prevent damage occurring to DNA; DNA repair mechanisms can repair any damage that does occur, 
and if these fail, the cell cycle can be arrested to induce senescence. All of those are working to 
prevent the formation of tumors. 
Another oncogenic protein suppressed by nuclear function is the protein MSP58, which  
Okumura et al. discovered transformed PTEN null mouse embryonic fibroblasts, yet was abrogated in 
the presence of introduced PTEN [200,201]. MSP58 was also abrogated by phosphatase inactive 
PTEN mutant suggesting that, as with the other nuclear PTEN functions described earlier, this is done 
potentially through physical interaction of the C-terminal domain. 
One of the most commonly observed methods by which PTEN has been suppressed has been during 
transcription. Methylation of the PTEN promoter region has been associated with reduced PTEN 
expression in various cancers [202]. The RAS-RAF-MEK-ERK pathway has been demonstrated to 
have a link with aberrant down-regulation of PTEN transcription in both epithelial and fibroblast cell 
types in human cancer cells through the factor c-Jun [33,203] and through transforming growth factor 
beta (TGFβ) dependent mechanism in pancreatic adenocarcinoma. miRNAs, and miR-21, in particular, 
disrupts expression of PTEN through binding to transcripted sequences [41,42]. 
As well as the nuclear functions regarding p53 described above, the suppression of PTEN would 
obviously lead to the unregulated behavior of the PI3K/AKT pathway leading to uncontrolled 
proliferation and cell growth. This would result in the proliferation of cells containing, potentially, 
deleterious segments of DNA, which may result in tumors. 
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There is also positive regulation of PTEN involved when regarding cancer. Tuberous sclerosis 1 
and 2 (TSC1 and TSC2) forms a complex that inhibits mTOR and so inhibits S6K [204]. Along with 
reducing insulin resistance, this also reduces the nuclear export of PTEN. The TSC1 and 2 complexes, 
however, are down-regulated by AKTA via phosphorylation of TSC1. This phosphorylation leads to 
the degradation of the TSC1 and 2 complexes, disallowing it from inhibiting mTOR. Both TSC1 and 
TSC2 are tumor suppressors and are mutated in tuberous sclerosis (TSC). TSC is associated with 
benign hamartomas and brain abnormalities [119], much like PHTS, although both are required for 
efficient TSC suppression. As the TSC1 and 2 complex helps reduce incidence of PTEN nuclear 
export, and PTEN reduces AKT phosphorylation of the TSC1 and 2 complexes, one can see that the 
tumor suppressive functions of PTEN are much broader than only its own syndromes. 
5. Conclusions 
To sum up a lengthy report: PTEN has significant implications for extending human longevity 
through its actions on DNA-damage reduction, antioxidant activity, caloric restriction, inhibition of 
replication and tumor suppression. The importance cannot be overstated as PTEN overexpression can 
assist a variety of maladies including weight-related diseases such as diabetes to age-related diseases 
such as Alzheimer’s and Parkinson’s. Its function as a tumor suppressor can maintain an anguish-free 
life. It is because of this variety and necessity of function that PTEN is a vital subject for  
further research. 
Through studies done on invertebrates [160–162] and on mammals [4] we have seen that the 
application of this knowledge is successful, that PTEN’s effect on longevity is not merely theoretical 
but practical. That PTEN can enhance longevity is no longer questionable, but neither is it irrefutable. 
Before any final concluding statements can be made, human trials with PTEN transfection must first 
be done. The authors of this study are currently working on cell culture trials, which is only the first step. 
PTEN alone cannot extend longevity indefinitely, however, Ortega-Molina et al. [4] found only a  
9%–16% increase in longevity, and while this is a significant milestone, this is hardly the fountain of 
youth that Ponce de León dreamt of. This is not to say that such a dream may not happen, merely that 
PTEN alone would not accomplish it. Jaskelioff et al. presented findings that telomerase can reverse 
tissue damage in aged mice [14]. This rejuvenative quality bodes well as a potential partner for PTEN, 
and its most important feature, that of telomere extension, could potentially extend longevity as long as 
needed. PTEN is well suited as a partner for telomerase due to its tumor suppressive quality. This is 
because of two reasons. Telomerase have been commonly associated with cancer and a tumor 
suppressor may prevent this. However, more importantly, the longer one lives, the probability of 
having cancer increases. It is PTEN’s tumor suppressive quality that sets it apart from other recent 
studied genes such as SIRT1. 
The variety of genes, proteins and enzymes being studied today show how the interconnectivity of 
the human system also necessitates a complex solution to longevity. Whether this is achieved through 
the main pathways of telomerase, SIRT1, PTEN or others remains to be seen. What must be done now 
is testing, and further testing, until an answer is found. With the importance of such work, it deserves 
no less. While human trials oblige a lengthy testing time, it is an inevitable obstacle that must be 
overcome if Pons de León’s dream is to be fulfilled. 
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